Evidence map›Paper›PMID 35747361›Full record

ArticleRSC advances2021

Yang Zhou, Guanglin Kuang, Junhao Li, Christer Halldin, Agneta Nordberg, Bengt Långström, Yaoquan Tu, Hans Ågren

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Development ofACS chemical neuroscience · 2022
    Article
  3. RSC advances · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yang ZhouSchool of Pharmacy, Jinan University Guangzhou 510632 China.
Guanglin KuangDivision of Theoretical Chemistry and Biology, School of Biotechnology, Royal Institute of Technology (KTH), AlbaNova University Center S-106 91 Stockholm Sweden.
Junhao LiDivision of Theoretical Chemistry and Biology, School of Biotechnology, Royal Institute of Technology (KTH), AlbaNova University Center S-106 91 Stockholm Sweden.
Christer HalldinKarolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatric Research 171 76 Stockholm Sweden.
Agneta NordbergNordberg Translational Molecular Imaging Lab, Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet 141 84 Stockholm Sweden.ORCID https://orcid.org/0000-0001-7345-5151
Bengt LångströmDepartment of Chemistry, Uppsala University SE- 751 23 Uppsala Sweden.
Yaoquan TuDivision of Theoretical Chemistry and Biology, School of Biotechnology, Royal Institute of Technology (KTH), AlbaNova University Center S-106 91 Stockholm Sweden.ORCID https://orcid.org/0000-0001-8198-9284
Hans ÅgrenDepartment of Physics and Astronomy, Uppsala University Box 516 SE-751 20 Uppsala Sweden.ORCID https://orcid.org/0000-0002-1763-9383

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The α7 nicotinic acetylcholine receptor (α7-nAChR) is implicated in a variety of neurodegenerative and neuropsychiatric disorders, such as Alzheimer's disease (AD) and schizophrenia. The progress of these disorders can be studied using positron emission tomography (PET) with radiotracers for α7-nAChR. [

Identifiers

PMID35747361
PMCPMC9134020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.